Profound Medical logo

PRN - Profound Medical Share Price

C$22.84 0.3  1.2%

Last Trade - 11/05/21

Small Cap
Market Cap £271.5m
Enterprise Value £213.4m
Revenue £5.17m
Position in Universe 441st / 2705
Unlock PRN Revenue
Relative Strength (%)
1m -11.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -37.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 3.78 2.01 4.17 7.30 16.0 34.1
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ProfoundMedical Corp revenues increased 75% to $7.3M. Net lossincreased 42% to $21.6M. Revenues reflect Canada segmentincrease from $2.4M to $5.2M, Germany segment increase of19% to $2.1M. Higher net loss reflects Finland segmentincome decrease of 15% to $2.2M. Basic Earnings per Shareexcluding Extraordinary Items increased from -$1.37 to-$1.25.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


PRN Revenue Unlock PRN Revenue

Net Income

PRN Net Income Unlock PRN Revenue

Normalised EPS

PRN Normalised EPS Unlock PRN Revenue

PE Ratio Range

PRN PE Ratio Range Unlock PRN Revenue

Dividend Yield Range

PRN Dividend Yield Range Unlock PRN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PRN EPS Forecasts Unlock PRN Revenue
Profile Summary

Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company’s products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated July 16, 2014
Public Since September 24, 2014
No. of Shareholders: n/a
No. of Employees: 109
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange Toronto Stock Exchange
Shares in Issue 20,340,219
Free Float (0.0%)
Eligible for
PRN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PRN
Upcoming Events for PRN
Wednesday 12th May, 2021
Q1 2021 Profound Medical Corp Earnings Release
Wednesday 12th May, 2021
Q1 2021 Profound Medical Corp Earnings Call
Wednesday 19th May, 2021
Profound Medical Corp Annual Shareholders Meeting
Thursday 20th May, 2021 Estimate
Profound Medical Corp Annual Shareholders Meeting
Frequently Asked Questions for Profound Medical
What is the Profound Medical share price?

As of 11/05/21, shares in Profound Medical are trading at C$22.84, giving the company a market capitalisation of £271.5m. This share price information is delayed by 15 minutes.

How has the Profound Medical share price performed this year?

Shares in Profound Medical are currently trading at C$22.84 and the price has moved by 21.49% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Profound Medical price has moved by -6.63% over the past year.

What are the analyst and broker recommendations for Profound Medical?

Of the analysts with advisory recommendations for Profound Medical, there are there are currently 3 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Profound Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Profound Medical next release its financial results?

Profound Medical is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Profound Medical dividend yield?

Profound Medical does not currently pay a dividend.

Does Profound Medical pay a dividend?

Profound Medical does not currently pay a dividend.

When does Profound Medical next pay dividends?

Profound Medical does not currently pay a dividend.

How do I buy Profound Medical shares?

To buy shares in Profound Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Profound Medical?

Shares in Profound Medical are currently trading at C$22.84, giving the company a market capitalisation of £271.5m.

Where are Profound Medical shares listed? Where are Profound Medical shares listed?

Here are the trading details for Profound Medical:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: PRN
What kind of share is Profound Medical?

Based on an overall assessment of its quality, value and momentum, Profound Medical is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Profound Medical share price forecast 2021?

Shares in Profound Medical are currently priced at C$22.84. At that level they are trading at 39.56% discount to the analyst consensus target price of 0.00.

Analysts covering Profound Medical currently have a consensus Earnings Per Share (EPS) forecast of -0.9428028763 for the next financial year.

How can I tell whether the Profound Medical share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Profound Medical. Over the past six months, the relative strength of its shares against the market has been -17.17%. At the current price of C$22.84, shares in Profound Medical are trading at -9.27% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Profound Medical PE Ratio?

We were not able to find PE ratio data for Profound Medical.

Who are the key directors of Profound Medical?

Profound Medical's management team is headed by:

Arun Menawat - CHM
Brian Ellacott - IND
Steve Forte - IND
Kenneth Galbraith - IND
Jean-Francois Pariseau - IND
Aaron Davidson - CFO
Rashed Dewan - CFO
Guruprit Singh - VPR
Mathieu Burtnyk - VPR
Murielle Lortie - DRC
Who are the major shareholders of Profound Medical?

Here are the top five shareholders of Profound Medical based on the size of their shareholding:

BDC Venture Capital Venture Capital
Percentage owned: 6.61% (1.34m shares)
Deerfield Management Company, L.P. Hedge Fund
Percentage owned: 5.12% (1.04m shares)
Fidelity Investments Canada ULC Investment Advisor
Percentage owned: 5.04% (1.03m shares)
Fidelity True North Fund Mutual Fund
Percentage owned: 5.04% (1.03m shares)
Letko, Brosseau & Associates Inc. Investment Advisor
Percentage owned: 4.13% (840k shares)
Similar to PRN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.